BioPharmSignal logoBioPharmSignal

Biotech News

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Benitec Biopharma (BNTC)Benitec BiopharmaFDA / regulatory

BNTC (BNTC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bntc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BNTCBenitec Biopharma2026-10-05 12:00 EST

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

BNTCBenitec Biopharma2026-03-09 11:00 EST

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

RHHBYRoche Holdings AG2026-09-30 05:00 EST

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

PHARPharming Group2026-03-24 06:00 EST

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

PHARPharming Group2026-09-25 14:30 EST

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

BNTXBioNTech2026-08-27 20:30 EST

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

RHHBYRoche Holdings AG2026-09-10 05:00 EST

U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments

ABUSArbutus2025-05-07 06:01 EST

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

BPTHBio-Path Holdings2025-02-12 21:01 EST

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

View all latest news

Benitec Biopharma

Benitec Biopharma is a gene-silencing biotechnology company focused on DNA-directed RNA interference and genetic medicine. Its story is built around platform science that aims to durably suppress disease-causing genes.

Recent company news

BNTCBenitec Biopharma2026-10-05 12:00 EST

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

BNTCBenitec Biopharma2026-09-14 20:00 EST

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

BNTCBenitec Biopharma2026-05-14 12:00 EST

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

BNTCBenitec Biopharma2026-04-28 11:00 EST

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

BNTCBenitec Biopharma2026-03-10 11:00 EST

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Stock data

Close
8.98 USD
Market cap
363.47M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States